SMT201500189T1 - Ligandi sigma per la prevenzione o il trattamento del dolore indotto da chmioterapia - Google Patents

Ligandi sigma per la prevenzione o il trattamento del dolore indotto da chmioterapia

Info

Publication number
SMT201500189T1
SMT201500189T1 SM201500189T SM201500189T SMT201500189T1 SM T201500189 T1 SMT201500189 T1 SM T201500189T1 SM 201500189 T SM201500189 T SM 201500189T SM 201500189 T SM201500189 T SM 201500189T SM T201500189 T1 SMT201500189 T1 SM T201500189T1
Authority
SM
San Marino
Prior art keywords
chemotherapy
prevention
treatment
induced pain
sigma ligands
Prior art date
Application number
SM201500189T
Other languages
English (en)
Italian (it)
Inventor
Jose Manuel Baeyens-Cabrera
Helmut Heinrich Bushcmann
Hernandez Jose Miguel Bela
Daniel Zamanillo-Castanedo
Francisco-Rafael Nieto-Lopez
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of SMT201500189T1 publication Critical patent/SMT201500189T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SM201500189T 2009-08-14 2015-08-05 Ligandi sigma per la prevenzione o il trattamento del dolore indotto da chmioterapia SMT201500189T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09382144A EP2292236A1 (en) 2009-08-14 2009-08-14 Sigma ligands for the prevention or treatment of pain induced by chemotherapy
EP10755460 2010-08-12
PCT/EP2010/061720 WO2011018487A1 (en) 2009-08-14 2010-08-12 Sigma ligands for the prevention or treatment of pain induced by chemotherapy

Publications (1)

Publication Number Publication Date
SMT201500189T1 true SMT201500189T1 (it) 2015-09-07

Family

ID=41531868

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201500189T SMT201500189T1 (it) 2009-08-14 2015-08-05 Ligandi sigma per la prevenzione o il trattamento del dolore indotto da chmioterapia

Country Status (34)

Country Link
US (3) US20120141606A1 (enExample)
EP (2) EP2292236A1 (enExample)
JP (1) JP5922575B2 (enExample)
KR (3) KR20170125951A (enExample)
CN (1) CN102497864B (enExample)
AR (1) AR077876A1 (enExample)
AU (2) AU2010283761B2 (enExample)
BR (1) BR112012003053A2 (enExample)
CA (1) CA2770441C (enExample)
CO (1) CO6511240A2 (enExample)
CY (1) CY1116697T1 (enExample)
DK (1) DK2464356T3 (enExample)
EC (1) ECSP12011658A (enExample)
ES (1) ES2543645T3 (enExample)
HR (1) HRP20150788T1 (enExample)
HU (1) HUE025642T2 (enExample)
IL (1) IL217911A0 (enExample)
IN (1) IN2012DN02149A (enExample)
MA (1) MA33569B1 (enExample)
MX (1) MX2012001877A (enExample)
MY (1) MY157334A (enExample)
NZ (1) NZ598213A (enExample)
PH (1) PH12012500286A1 (enExample)
PL (1) PL2464356T3 (enExample)
PT (1) PT2464356E (enExample)
RU (1) RU2543382C2 (enExample)
SG (1) SG178338A1 (enExample)
SI (1) SI2464356T1 (enExample)
SM (1) SMT201500189T1 (enExample)
TN (1) TN2012000048A1 (enExample)
TW (1) TWI529168B (enExample)
UA (1) UA108859C2 (enExample)
WO (1) WO2011018487A1 (enExample)
ZA (1) ZA201200843B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2426111A1 (en) * 2010-08-09 2012-03-07 Laboratorios Del. Dr. Esteve, S.A. 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms
EP2524694A1 (en) * 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
EP2792352A1 (en) 2013-04-16 2014-10-22 Laboratorios Del. Dr. Esteve, S.A. Alpha-2 adrenoreceptor and sigma receptor ligand combinations
MX2016002892A (es) * 2013-09-12 2016-06-10 Esteve Labor Dr Combinaciones de ligando de receptores sigma y aine.
SG11201604480PA (en) 2013-12-17 2016-07-28 Esteve Labor Dr SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS
MX2016007286A (es) 2013-12-17 2016-08-04 Esteve Labor Dr Combinaciones de gabapentinoides y ligandos de receptores sigma.
AR108682A1 (es) * 2016-06-06 2018-09-12 Esteve Labor Dr Derivados de pirazol-3-iloxi ligandos del receptor sigma
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2024105225A1 (en) * 2022-11-18 2024-05-23 Universitat De Barcelona Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU11248A1 (ru) 1927-03-29 1929-09-30 В.С. Григорьев Способ очистки антрацена
FR2301250A1 (fr) * 1975-02-21 1976-09-17 Bellon Labor Sa Roger Nouveaux diaryl-1, 4o-aminoalcoxy-3 pyrazoles et leurs sels
MX2007002341A (es) * 2004-08-27 2007-09-25 Esteve Labor Dr Inhibidores del receptor sigma.
KR101352012B1 (ko) * 2004-08-27 2014-01-15 라보라토리오스 델 드라. 에스테브.에스.에이. 시그마 수용체 저해제
EP1634872A1 (en) * 2004-08-27 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Pyrazole derivatives as sigma receptor inhibitors
CN101395157A (zh) * 2006-03-01 2009-03-25 伊斯特芬博士实验室有限公司 作为西格玛受体抑制剂的吡唑衍生物
WO2007098953A1 (en) * 2006-03-01 2007-09-07 Laboratorios Del Dr. Esteve, S.A. Pyrazole derivatives as sigma receptor inhibitors

Also Published As

Publication number Publication date
MY157334A (en) 2016-05-31
KR20170125951A (ko) 2017-11-15
UA108859C2 (uk) 2015-06-25
AU2016228207A1 (en) 2016-11-03
AU2010283761B2 (en) 2016-10-13
US20160199380A1 (en) 2016-07-14
US20160220575A1 (en) 2016-08-04
ES2543645T3 (es) 2015-08-20
WO2011018487A1 (en) 2011-02-17
RU2543382C2 (ru) 2015-02-27
CA2770441A1 (en) 2011-02-17
TWI529168B (zh) 2016-04-11
IL217911A0 (en) 2012-03-29
EP2464356B1 (en) 2015-05-06
DK2464356T3 (en) 2015-07-13
AR077876A1 (es) 2011-09-28
NZ598213A (en) 2014-05-30
CY1116697T1 (el) 2017-03-15
CN102497864B (zh) 2015-07-22
AU2010283761A1 (en) 2012-03-08
US20120141606A1 (en) 2012-06-07
HK1171945A1 (en) 2013-04-12
TN2012000048A1 (en) 2013-09-19
MA33569B1 (fr) 2012-09-01
EP2292236A1 (en) 2011-03-09
JP2013501754A (ja) 2013-01-17
MX2012001877A (es) 2012-04-11
JP5922575B2 (ja) 2016-05-24
SG178338A1 (en) 2012-03-29
ZA201200843B (en) 2012-10-31
AU2016228207B2 (en) 2017-09-07
CN102497864A (zh) 2012-06-13
CA2770441C (en) 2017-12-12
KR101605151B1 (ko) 2016-03-21
BR112012003053A2 (pt) 2016-08-02
ECSP12011658A (es) 2012-03-30
EP2464356A1 (en) 2012-06-20
SI2464356T1 (sl) 2015-08-31
RU2012109554A (ru) 2013-09-20
PT2464356E (pt) 2015-08-31
KR20120055692A (ko) 2012-05-31
KR20150140419A (ko) 2015-12-15
PL2464356T3 (pl) 2015-10-30
CO6511240A2 (es) 2012-08-31
TW201121959A (en) 2011-07-01
HRP20150788T1 (hr) 2015-08-28
HUE025642T2 (en) 2016-04-28
IN2012DN02149A (enExample) 2015-08-07
PH12012500286A1 (en) 2015-06-26

Similar Documents

Publication Publication Date Title
SMT201600055B (it) Composizione farmaceutica per il trattamento o la prevenzione del glaucoma
IL253891A0 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
IL265774B (en) Diagnosis, prevention and treatment of joint diseases
EP2512240A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF TRIGEMINO AUTOMOTIVE ZEPHALGIA, MIGRAINE AND VASCULAR DISEASES
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
BRPI1006898A2 (pt) métodos de tratamento da síndrome do extravasamento vascular.
PL2582366T3 (pl) Kombinacja farmaceutyczna do leczenia bólu
BR112012002124A2 (pt) tratamento da doença de crohn com laquinimode.
IL217540A (en) Oral composition for use in oral disinfection or in treating an oral disease
HUE045367T2 (hu) Kombinált terápia diabétesz kezelésére
ATE538652T1 (de) Synergistische pharmazeutische kombination für die behandlung von krebs
HUE040085T2 (hu) PDE7 inhibitorok alkalmazása mozgási rendellenességek kezelésére
BR112012003053A2 (pt) ligantes sigma para a prevenção ou tratamento de dor induzida pela quimioterapia
SMT201900015T1 (it) Medicamento per uso topico a base di acido ialuronico solfatato per il trattamento dei coaguli di fibrina e dei trombi
ZA201203808B (en) Combination for the treatment of radiation-or chemotherapy-induced mucositis
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
GB0906159D0 (en) Drug combination for the treatment of proteostatic diseases
EP3381471C0 (en) PAIN TREATMENT
BRPI1009448A2 (pt) combinações farmacêuticas compreendendo edea119/bay 869766 para o tratamento de cânceres específicos
GB0904427D0 (en) Treatment of diseases related to hyperactivity of the complement system
IL225755B (en) amido derivatives - 6 of epoxymorphinans - a5, 4 for the treatment of pain
PL2731584T3 (pl) Zastosowanie związków oligosacharydowych do zapobiegania i leczenia patologicznych blizn
IL219050A0 (en) Pharmaceutical composition for the treatment of bladder disorders
IL207668A0 (en) Beloxepin, its enantiomers, and analogs thereof for the treatment of pain
HUP1200552A2 (en) Pharmaceutical compositions for the treatment of high blood pressure